Accustem Sciences Inc. is a clinical-stage diagnostics company developing proprietary genomic tests targeting lung nodules and early-stage breast cancer recurrence risk, addressing a combined US market opportunity exceeding $6.3 billion. Despite extensive clinical validation of their MSC and StemPrintER assays in thousands of patients, the company has yet to commence commercialization, relying heavily on external partners for CLIA certification, utility studies, and reimbursement efforts. Financially, Accustem continues to operate at substantial losses with very limited liquidity, posing material risks to its ability to execute growth plans amid a highly competitive oncology diagnostics market with complex regulatory and reimbursement challenges.